Lovastatin and Rhabdomyolysis
Authors: John Z. Ayanian
Journal: Annals of Internal Medicine (1988)

Letters and Corrections15 October 1988Lovastatin and RhabdomyolysisJohn Z. Ayanian, MD, Charles S. Fuchs, MD, Richard M. Stone, MDJohn Z. Ayanian, MDSearch for more papers by this author, Charles S. Fuchs, MDSearch for more papers by this author, Richard M. Stone, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-8-682 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, lowers serum cholesterol in both familial (1) and nonfamilial (2) forms of hypercholesterolemia. Rhabdomyolysis, occasionally resulting in renal failure, has been reported in 13 patients receiving lovastatin therapy 9 of whom were also receiving cyclosporine or gemfibrozil therapy (3, 4). We report a case of severe rhabdomyolysis in a patient being treated with both lovastatin and erythromycin; the case potentially represents a new adverse drug interaction.A 65-year-old man with a history of severe coronary artery disease and chronic renal failure had been...References1. HavelHunninghakeIllingworth RDD Lovastatin (Mevinolin) in the treatment of heterozygous familial hypercholesterolemia. Ann Intern Med. 1987;107:609-15. LinkGoogle Scholar2. . Therapeutic response to lovastatin (mevinolin) in non-familial hypercholesterolemia. JAMA. 1986;256:2829-34. CrossrefMedlineGoogle Scholar3. NormanIllingworthMunson DDJ Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med. 1988;318:46-7. CrossrefMedlineGoogle Scholar4. EastAlivizatosGrundy CPS Rhadomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988;318:47-8. CrossrefMedlineGoogle Scholar5. Ludden T. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet. 1985;10:63-79. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Brigham and Women's Hospital Harvard Medical School Boston, MA 02115 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySimvastatin Prevents Long-Term Cognitive Deficits in Sepsis Survivor Rats by Reducing Neuroinflammation and NeurodegenerationAmyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA’s Adverse Event Reporting SystemLovastatinMacrolide antibioticsInteracciones graves o potencialmente letales entre antirretrovirales y otros medicamentosCYP3A4: The WorkhorseOne pot synthesis of biologically active pregnane derivatives, their single crystal structures, spectroscopic characterization and theoretical calculationsUpdates on Cytochrome P450-Mediated Cardiovascular Drug InteractionsDrug Disposition and Drug–Drug Interactions: Importance of First-Pass Metabolism in Gut and LiverANTIBACTERIAL DRUGSUpdates on Cytochrome P450-Mediated Cardiovascular Drug InteractionsLIPID – REGULATING DRUGSSimvastatin-Associated Rhabdomyolysis After Coadministration of Macrolide Antibiotics in Two PatientsMacrolide antibioticsBench to Bedside: Pharmacogenomics, Adverse Drug Interactions, and the Cytochrome P450 SystemToxic MyopathiesComparative effects of lipid-lowering therapiesGenetic Polymorphisms in Cytochrome P450 EnzymesCombination lipid-lowering therapy with statins: safety issues in the postcerivastatin eraAntihyperlipidemic AgentsIatrogenic and toxic myopathiesChapter 32 Toxic myopathiesIssues in Hyperlipidemic PancreatitisA Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy VolunteersMyopathy and rhabdomyolysis with lipid-lowering drugs3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patientAcquired MyopathiesRhabdomyolysis and Satin Therapy: Relevance to the ElderlyPharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase InhibitorsRhabdomyolysis and HMG-CoA Reductase InhibitorsStatin—Fibrate Combination TherapyThe role of cytochrome P450-mediated drug-drug interactions in determining the safety of statinsRhabdomyolysis Secondary to a Drug Interaction between Simvastatin and ClarithromycinSafety Profiles for the HMG-CoA Reductase InhibitorsDoes differing metabolism by cytochrome P450 have clinical importance?HMG-CoA Reductase Inhibitors: Assessing Differences in Drug Interactions and Safety ProfilesMacrolide Drug Interactions: An UpdatePharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionNew insights into the pharmacodynamic and pharmacokinetic properties of statinsRhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarinReview and Comparison of Advanced-Generation Macrolides Clarithromycin and DirithromycinMetabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant PatientsAtorvastatin in the Treatment of Primary Hypercholesterolemia and Mixed DyslipidemiasLong-Term Efficacy and Safety of Fenofibrate and a Statin in the Treatment of Combined HyperlipidemiaLovastatin increases exercise-induced skeletal muscle injuryTOXIC MYOPATHIESLovastatin-Induced Rhabdomyolysis Possibly Associated with Clarithromycin and AzithromycinDrug Interactions with Agents Used in the Treatment of Cardiovascular DiseaseAction of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscleClinical pharmacologic concepts for the rational selection and use of drugs for the management of dyslipidemiaEffects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cellsIdentification of Human Liver Cytochrome P-450 3A4 as the Enzyme Responsible for Fentanyl and Sufentanil N-DealkylationApproaches to The Treatment of Hyperlipidemia in the Solid Organ Transplant RecipientLong-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients.Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapyThe pharmacology of fluvastatin, a new HMG-CoA reductase inhibitorRhabdomyolysis and acute renal failure after near‐drowning in cold salt waterDRUG-RELATED MYOPATHIESDrugs for treatment of patients with high cholesterol blood levels and other dyslipidemiasTolerability and efficacy of combination therapy with simvastatin plus gemfibrozil in type IIb refractory familial combined hyperlipidemiaBezafibrate induced rhabdomyolysis.Musculoskeletal Complications After Renal Transplantation: Pathogenesis and TreatmentLovastatin-Induced Rhabdomyolysis in the Absence of Concomitant DrugsRhabdomyolyse causée par la simvastatine chez un transplanté cardiaque sous ciclosporineEffects of exercise and lovastatin on serum creatine kinase activityNicotinic Acid for the Treatment of HyperlipoproteinemiaSimvastatin: A Review of its Pharmacology and Clinical UseDrugs in the Management of Lipid DisordersDrugs affecting lipid metabolismDrug-induced myopathiesRhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil TherapyGary E. Marais, MB, ChB, Kerry K. Larson, MDLong Term Clinical Tolerance of Lovastatin (Mevinolin) and Simvastatin (Epistatin)Lovastatin and Other HMG-CoA Reductase Inhibitors 15 October 1988Volume 109, Issue 8Page: 682-683KeywordsBiosynthesisCholesterolCoenzymesDrug interactionsEnzymesErythromycinRenal failureRhabdomyolysisStable coronary artery disease Issue Published: 15 October 1988 PDF DownloadLoading ...